



# Evaluation of MicroRNA as Minimal Residual Disease in Leukemia: Diagnostic and Prognostic Approach: A Review

*Bahareh Shateri Amiri*<sup>1</sup>, *Neda Sabernia*<sup>2</sup>, *Behdokht Abouali*<sup>3</sup>, *Parya Amini*<sup>4</sup>,  
*\*Hadi Rezaeeyan*<sup>5</sup>

1. Department of Internal Medicine, School of Medicine, Hazrat-e Rasool General Hospital, Iran University of Medical Sciences Tehran, Iran
2. Department of Internal Medicine, School of Medicine, Iran University of Medical Sciences, Tebran, Iran
3. Department of Ophthalmology, School of Medicine, Infectious Ophthalmologic Research Center, Abvaz Jundishapur University of Medical Sciences, Abvaz, Iran
4. Department of Cardiology, School of Medicine, Abvaz Jundishapur University of Medical Science, Abvaz, Iran
5. Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Iranian Blood Transfusion Organization, Tebran, Iran

**\*Corresponding Author:** Email: Hadi.rezaeeyan@yahoo.com

(Received 20 Feb 2023; accepted 19 May 2023)

## Abstract

Various factors are effective in the development of minimal residual disease (MRD), one of which is MicroRNAs (miRNAs). miRNAs and their dysfunction in gene expression have influential role in the pathogenesis of leukemia. Nowadays, treatments that lead to the suppression or replacement of miRNAs have been developed. Focusing on the role of miRNAs in managing the treatment of leukemia, in this review article we have investigated the miRNAs and signaling pathways involved in the process of apoptosis and cell proliferation, as well as miRNAs with oncogenic function in malignant leukemia cells. Among the studied miRNAs, miR-99a, and miR-181a play an essential role in apoptosis, proliferation and oncogenesis via AKT, MAPK, RAS, and mTOR signaling pathways. miR-223 and miR-125a affect apoptosis and oncogenesis via Wnt/B-catenin, PTEN/PI3K, and STAT5/AKT/ERK/Src signaling pathways. miR-100 also affects both apoptosis and oncogenesis; it acts via IGF1 and mTOR signaling pathways.

**Keywords:** MicroRNAs; Minimal residual disease; Pathogenesis; Prognosis; Diagnosis

## Introduction

Leukaemia is a range of malignant disorders, characterized by disruption of differentiation of blood progenitor cells. This group of malignancy occurs in all age ranges, although its different types have different age distribution in terms of disease incidence (1-3). The clinical manifestations of disease include fatigue, weakness, pallor,

bone pain, fever, lymphadenopathy, and arthralgia (4, 5). Acute leukemias are among the most prevalent cancers that affect people of all ages. The cause of acute leukemias is still unknown, although number of genetic and environmental factors have been suggested. A number of genetic and environmental factors have been suggest-



ed, but none has been demonstrated to cause acute leukemias. Genetic significantly influences the emergence of many disorders, and numerous environmental elements, professions, and past-times have been studied (6-8).

The genetic changes that contribute to the pathogenesis of leukemia vary and include mutations, deletion, insertion, and translocation. Based on the patient's condition and pathophysiology of disease, different treatment strategies are adopted; these include chemotherapy, immunotherapy, target therapy, radiotherapy, and hematopoietic stem cells transplantation (HSCT) (9).

Today, evaluation of minimal residual disease (MRD) is one of the common methods to assess the response to treatment (6, 10). Various techniques have been investigated to evaluate MRD; the use of these methods help to improve the prognosis of patients (6). The term MRD refers to the population of leukemia cells that have survived chemotherapy and radiation therapy and cause the disease to return. To forecast the outcome and choose the level of intensity for additional treatment techniques, MRD must be detected. Significant improvements in the sensitivity of MRD diagnosis have been made thanks to the development of numerous new diagnostic tools, including next-generation sequencing (NGS). Using phenotypic marker patterns or differential gene expression patterns, there are some techniques to diagnose MRD; reverse transcription polymerase chain reaction (RT-PCR), flow cytometry (FCM), or PCR are examples of these techniques. Practical viability and patient demand for improved diagnostic sensitivity will shape future advancements in the clinical treatments (11-13).

Various factors are influential in the development of MRD, one of which is Micro RNAs (miRNAs). These molecules regulate mRNA expression in the posttranscriptional level. miRNAs regulate about half of human genes (14-16). The profile of miRNAs in normal tissues and various diseases has been extensively studied despite limitations. These molecules are actively secreted into the extracellular space by extracellular vesicles

(14). This feature along with easy distribution in fluid and their stability has made them a good biomarker for MRD in leukaemia-involved patients (14).

EL-KHAZRAGY et al. emphasized on the pathogenesis role of miR-188a and miR-155a in many types of leukaemia (17). Moreover, miR-31 affects many cellular and developmental processes by targeting the impressive genes of proliferation, apoptosis and oncogenic activity (18-20). They are non-coding RNAs and can affect regulation of biological and pathological processes in many diseases, and the processes of proliferation, apoptosis, and oncogenic activity. Considering that few studies have been done in this field, we investigated the role of miRNAs in MRD.

#### *miRNAs as oncogenic factor*

miRNAs deregulation can lead to the onset and progression of disease (21, 22). Therefore, miRNAs can be used as the potential therapeutic candidates, also studies have shown that these molecules can be used as the diagnostic and prognostic biomarkers in the patients (23, 24).

In patients with leukaemia, increased expression of miR-200c/141 and miR-181a/181b through down regulation of TGF $\beta$  signalling pathway is clearly related to increased WBC count and poorer prognosis (19, 25, 26). In patients with leukaemia, clonal arrest of B cells occurs in the G0/G1 phase of the cell cycle, associated with clonal proliferation of B cells. This proliferation depends on increasing the expression of miR-22, which leads to phosphatase and tensin homolog (PTEN) down regulation and activation of PI3K/AKT pathway. Accordingly, PI3K inhibitors are used in the treatment of these patients (28-29).

miR-335/ID4 causes Leukemogenesis by activating the PI3K/AKT signalling pathway. Accordingly, aberrant expression of miR-335/ID4 is considered as a prognostic biomarker in leukaemia and can be used for therapeutic purposes (Figs.1,2) (30). miR-335 overexpression results in up regulation of BRCA1 mRNA expression indicating the functional domain of ID4 signalling. The relevance of miR-335 regulation for human

breast cancer has been confirmed in most of sporadic breast cancer samples with significantly reduced levels of miR-335 (31). miR-625 is involved in many biological processes such as invasion, migration, apoptosis, cell proliferation, cell cycle regulation, and drug resistance (32-34). In thyroid cancer, suppressing the miR-625-3p inhibits cell proliferation through inactivating the PI3K/AKT and MEK/ERK signaling pathways (24, 32).

miR-100 and miR-99a play a role through two signalling pathways, the first is the suppression of the IGF1R/mTOR signalling pathway and down regulation of the anti-apoptotic genes, i.e., *MCL1*, which leads to the inhibition of cell proliferation and the apoptosis induction. The second pathway is related to glucocorticoid receptors through the suppression of the FKBP51 signalling pathway, which leads to increased activity of glucocorticoid receptors (35-39).

Increased expression of miR-106b-5p and miR-26b-5p leads to disease progression. The study of several patients with leukaemia has shown the key role of miR-26b-5p in leukaemia (40-42). Its increased expression leads to the inhibition of the TGF-B/SMAD signalling pathway, which results in down expression of *P21-G1P1kinase* inhibitor and high expression of *c-MYC* oncogene. The mentioned events lead to increase in the proliferation of leukemic cells and the leukemic clone; this mechanism is influential in the treatment strategies of leukemic patients (40).

Increased expression of *miR-362-5p* as oncomiR through *GADD45a* down regulation and decreased expression of *miR-320a* as tumour suppressor through PI3K/AKT and NF-kb pathway are involved in the migration and invasion pathway (43). In this way, increasing the expression of *miR-320a* by inhibiting the phosphorylation of mentioned pathways leads to weakening the oncogenic function of bcr/abl (44).


Meanwhile, increasing its expression in THP-1 human leukaemia monocytic cell line produces the opposite result. By targeting DAB2, miR-93 inhibits the PI3K/AKT signalling pathway and increasing *DAB2* expression negatively affects the growth of THP-1 cells (44). miR-125a acts as

a tumour suppressor in patients with leukaemia. Increasing its expression by inhibiting the Erb signalling pathway leads to inhibiting the cycle of cell proliferation and increasing the apoptosis rate of leukemic cells (45). On the other hand, in some leukaemia patients, increasing its expression through the signalling pathway leads to resistance to apoptosis and reduced response to treatment. In fact, miR-125a also acts like a double-edged sword, identifying the related signalling pathways leads to better management of the treatment of patients with leukaemia (45-46).

Expression of miR-142-3p as an oncogene increased in leukaemia. Its high level of expression is related to the worse prognosis of disease. This oncogenic role is justified by targeting the cyclic adenosine monophosphate (cAMP), PKA (protein kinase A), GR (glucocorticoid receptor) alpha. Increased expression of *miR-142-3P* leads to decrease in the *cAMP* level and *PKA* activity and eliminates the inhibitory effect of PKA on the proliferation of leukemic cells (47-49).

The expression of *EXT1* decreases in patients with leukaemia; it is inversely related to the expression of miR-665 (50). Furthermore, decrease in the expression of *EXT1* and increase in the expression of miR-665 are associated with poor prognosis in these patients. *EXT1* through inactivation of the pathway ERK1/2 signalling leads to apoptosis induction in AML cells (50). In patients with leukaemia, increased expression of *miR-204* leads to the suppression of proliferation, migration, and cell invasion and induction of apoptosis in leukemic cells. Hepatic growth factor (HGF) is up regulated in leukemic cells (51). By directly targeting HGF, miR-204 regulates the c-MYT signalling pathway; in fact, it has an inhibitory effect on the progression of AML through the HGF/c-MYT pathway (52, 53).

MiR-181a directly binds to 3'UTRs, which results in *KRAS*, *NRAS*, and *MAPK1* downregulation and decreased leukemic cell proliferation in AML. Inhibited colony formation, decreased proliferation, and greater sensitivity to chemotherapy are all effects of elevated miR-181a expression (Fig.1) (54, 55).



**Fig. 1:** Role of miRNAs in MRD: miR-181a , miR-100 and miR-99a play an important role in MRD through KRAS, mTOR, and Akt signaling pathways. Activation of Wnt/B-catenin and inhibition of PI3K/AKT signaling pathways by miR-139-5P leads to proliferation of leukemic cells (Original Figure)

### Involved miRNAs in apoptosis

Leukaemia cells have abnormalities in one or more of apoptosis signalling pathways (Table1, Fig.2) (56). miR-3151, as a tumour growth suppressing factor in patients with leukaemia, undergoes a decrease in gene expression and hyper methylation; by increasing the activity of MEK/ERK and PI3K/AKT pathways and increasing the expression of *MCL1*, it protects the malignant cells against apoptosis (52, 56, 57).

miR-378 dysregulation occurs in various types of leukaemia. The level of miR-378 is clearly higher in patients with leukaemia. Increased expression of miR-378 in malignant cells leads to increased cell proliferation and drug resistance. Apoptosis is inhibited in cells transfected with miR-378. Increase in miR-378 expression is actually associated with up regulation of stem cell markers of *OCT4* and *c-Myc* (58). Meanwhile, in colorectal cancer miR-378-5P leads to inhibition of cell proliferation and induction of apoptosis through the RAS/RAF/MEK signalling pathway (59). Increased expression of miR-34 in leukaemia patients leads to apoptosis through inhibition of PI3K/Akt signalling pathway, and inhibits autophagy in leukaemia cells (60).

In malignant cells, miR-99a down regulation and methylenetetrahydrofolate dehydrogenase 2 (*MTHFD2*) up regulation occurs in some types of leukaemia. In fact, *MTHFD2* knocking down and increased expression of miR-99a lead to in-

hibition of cell proliferation and induction of apoptosis (61, 62). miR-99a induces apoptosis and inhibits cell proliferation by inhibiting the AKT signalling pathway by targeting the *MTHFD2* (61).

Increased expression of *miR-140-5p* leads to decreased cell proliferation and induction of apoptosis through sine oculis homebox 1(*SIX1*) in leukemic cells (63). In fact, inhibition of *SIX1* expression by inhibiting the STAT3 signalling pathway clearly leads to cell proliferation decrement in leukemic cells and induction of apoptosis through increased expression of proteins related to apoptosis, such as Bcl-2, Bax, and caspase-3. This path can be used as a therapeutic goal in the treatment of leukaemia (63).

miR-582-5p in patients with leukaemia leads to inhibition of cell proliferation, induction of apoptosis and suppression of cell invasion and migration. Its increased expression leads to the expression of two markers involved in cell apoptosis, namely Cleaved caspase-3 and Cleaved PARP proteins (64). miR-34 in leukemic cells is associated with poor prognosis and reduced response to treatment. In fact, miR-34a expression through targeting the pathway Janus kinase 1-signal transducer and activator of transcription 2-p53 axis signalling leads to stimulation of cell death in leukemic cells (64, 65).

By targeting the 3' UTR of FKBP51, the expression of *miR-100* reduces and this effect leads to

cell proliferation and inhibition of apoptosis (66). The expression of miR-125a decreases in patients with leukaemia (28). By increasing its expression, the activity of the ErbB signalling pathway decreases and leads to inhibition of cell proliferation and induction of apoptosis. Mubritinib is used to treat some types of leukaemia; it inhibits the ErbB pathway and increases the expression of miR-125a (45).

*miR-486-5p* is clearly down regulated in leukemic cells. Its increased expression leads to apoptosis induction, increased caspase-3 activity in malignant cells, and decreased *FOXO1* expression (67). *RaLA* is a downstream molecule and a component of the bcr-abl fusion protein in the RAS signalling pathway (24). This molecule is the target of miR-181a in leukemic cells. Increased expression of miR-181a leads to cell proliferation sup-

pression and stopping cell proliferation in the stage of G2 and induction of apoptosis in the K562 leukemic cells (68).

*miR-1271-5p* is down regulated in patients with leukaemia. Increasing its expression leads to induction of apoptosis in leukemic cells. The translational factor *ZIC2* is the direct target of *miR-1271-5p*; it decreases cell proliferation and increases apoptosis through the reduction of *ZIC2* expression. It also plays the same role in ovarian cancer by inhibiting the NOTCH signalling pathway, and leads to the inhibition of proliferation (5, 69). Increased expression of *miR-451a* in patients with various types of leukaemia leads to cell proliferation inhibition; it also results in down regulation of *c-Myc* oncogene through IL-6R and inhibition of activation of JAK and STAT3 signalling pathways (70).

**Table 1:** Summary of miRNAs involved in apoptosis

<i>miRNAs</i>	<i>Altered expression</i>	<i>Target</i>	<i>Mechanism</i>	<i>Ref.</i>
miR-9	↑	<i>Hes1</i>	<i>Hes1</i> inhibiting miR-9 and reduce growth cell	(71)
miR-21	↑	<i>PTEN/AKT pathway</i>	Inhibiting <i>miR-21</i> cause apoptosis	(72)
miR-29b	↓	<i>MCL-1</i> <i>CXXC6</i> <i>CDK6</i>	It leads to proliferation and inhibiting apoptosis	(73)
miR-125b	↑	<i>NF-κB</i>	It inhibits the invasion, proliferation, and death of human leukemic cells.	(74)
miR-126	↑	<i>PLK2</i>	It increases cell viability and prevents cell death	(75)
miR-135a	↓	<i>HOXA10</i>	<i>miR-135a</i> overexpression induces cellular death while suppressing cell growth and the cell cycle.	(76)
miR-143	↑	<i>ERK5</i>	Apoptosis is induced by an increase in the granulocyte surface marker Ly6G and a more developed morphology toward granulocytes.	(77)
miR-150	↓	<i>EIF4B</i> , <i>FOXO4</i> , <i>PRKCA</i> , <i>TET3</i>	In both vitro and vivo, it promotes cell proliferation and prevents apoptosis.	(78)

### *Involved miRNAs in proliferation*

Various molecular, genetic, and cytogenetic abnormalities are effective in the clonal expansion and proliferation of blood progenitor cells (Table.2, Fig.2). Aberrant expression of *miR-181a* in

leukemic cells clearly leads to increased cell proliferation through activation of Akt signalling pathway (79). The expression of *miR-1193* in leukemic cells significantly reduces the proliferation and invasion of malignant cells. In breast cancer,



miR-1193 reduces the proliferation of malignant cells through the activation of the PI3K/Akt signalling pathway (80). In patients with leukaemia, increase in the expression of *miR-99a* and miR-100 leads to the inhibition of cell proliferation by inactivating the mTOR signalling pathway and inhibiting the IGF1R gene expression (35).

In leukemic cells, miR-139-5p leads to the inhibition of cell proliferation by inactivating the Wnt/B-catenin signalling pathway (81). In patients with leukaemia, the expression of *miR-582-5p* leads to inhibition of cell proliferation and induction of apoptosis. In patients with non-small cell lung cancer (NSCLC), miR-582-5p plays the same role by inhibiting the hippo-yap/taz signalling pathway (64). The increased expression of *miR-141-5p* reduces the proliferation of leukemic cells and accelerates apoptosis. While expression in prostate cancer leads to the development of metastasis through the activation of the NF-KB signalling pathway (82). miR-132 and miR-212 lead to increased proliferation and invasion of leukemic cells; they play the same role in various

cancers by inhibiting the TGF beta and PI3K signalling pathways (83).

miR-125ba leads to the acceleration of cell proliferation of leukemic cells by increasing the activity of PI3K/Akt, NF-kB and MAPK signalling pathways (84). In patients with leukaemia, *miR-182* expression reduction widely leads to decrease in cell proliferation, and its expression decrease by inhibiting the TLR4/NF-kB signalling pathway in malignant breast cancer cells; it leads to decrease in cell proliferation and invasion (85). In leukemic cells, the expression of *miR-15a* and *miR-16* leads to the proliferation of malignant cells (16). In prostate cancer, miR-15a/16 inhibits the TGF-beta signalling pathway and leads to disease progression and metastasis (86). On the other hand, in patients with papillary thyroid cancer, increased expression of miR-15 inhibits the proliferation of malignant cells through inhibiting the RET/Akt signalling pathway; so, its dual role can play an important role in managing the treatment of patients with leukaemia (86).

**Table 2:** Summary of miRNAs involved in proliferation


<i>miRNAs</i>	<i>Altered expression</i>	<i>Target</i>	<i>Mechanism</i>	<i>Ref.</i>
miR-9	↓	<i>HMG42</i> <i>LIN28B</i>	Cause cell proliferation	(91)
miR-9	↓	<i>RUNX1</i> , <i>RUNX1T1</i> , <i>RUNX1- RUNX1T1</i>	Inhibiting differentiation, and cause proliferation	(92)
miR-9	↓	<i>SIRT1</i>	Cause reduce proliferation of cells	(93)
miR-9	↓	<i>FOXO1</i> <i>FOXO3</i>	Cause cell proliferation	(94)
miR-21	↑	<i>PTEN/AKT pathway</i>	Cause reduces proliferation of cells	(72)
miR-29b	↓	<i>SP1</i>	Cause cell proliferation.	(95)
miR-34a	↓	<i>E2F3</i>	Boost proliferation while reducing differentiation.	(96)
miR-135a	↓	<i>HOXA10</i>	Inhibiting differentiation, and cause proliferation	(76)

In leukaemia, miR-124 leads to the acceleration of cell proliferation and resistance to glucocorticoid treatment. Also, in bladder cancer by inhibit-

ing the STAT3 signalling pathway, it leads to apoptosis induction and increased cell proliferation (87). miR-223 leads to decrease in the

growth rate and suppresses the proliferation of leukemic cells; it performs this role by inhibiting the Akt/mTOR/p70S6K signalling pathway (88). miR-205 leads to the inhibition of cell prolifera-

tion in leukemic cells. In gastric cancer, it plays this role by inhibiting the Akt signalling pathway (89-90).



**Fig. 2:** Role of miRNAs in proliferation, apoptosis and oncogenes related MRD. miR-223, miR-125a, miR-139-5p, miR-181a, and miR-99a are involved as oncogenes. miR-99a, miR-100, miR-125a, and miR-181a are also involved in apoptosis. miR-181a, miR-99a, miR-139-5p, and miR-223 are involved in proliferation (Original Figure)

**Strategy and potential therapeutic**

Clinical trials and ongoing researches are actively working to personalize the therapy through the discovery of molecular targets, identification of patient- and disease-specific risk factors, and the identification of potent medication and modality combinations. In Table 3, the drugs used as target therapy in leukemia and their mechanisms are listed. One of the therapeutic strategies to pre-

vent MRD is targeting the miRNAs (97). In many cases, these paths are double-edged swords. On the one hand, it inhibits MRD. In addition, targeting the miRNAs can also affect the activity of LncRNAs. The factors in the downstream of miRNAs play a role in the sensitivity of cells to chemotherapy. Some of these factors play a role in the sensitivity of cells to apoptosis (98).

**Table 3:** Drugs used as targeted therapy and their mechanisms in leukemia

Drug	Mechanism	miRNA	Ref.
Venetoclax	Selective small molecule BCL2 inhibitor blocks the anti-apoptotic B-cell lymphoma-2 (Bcl-2) protein, and causes apoptosis of CLL cells. Overexpression of Bcl-2 has been linked to increased resistance to chemotherapy.	miRNA-15/16	(99)
Dasatinib- Blinatumomab	Inhibiting BCL-2 and cause induced apoptosis	miRNA-378 and miRNA-17	(100)
Asciminib	Dasatinib targeting BCR/Abl, Src, c-Kit, ephrin receptors.	miRNA-21-5p miR-139-5p	(68)
Acalabrutinib	Blinatumomab binding to CD3 and CD19.	miR-210	(47)
Vemurafenib	Targeting the ABL myristoyl pocket.	miR-204-5p and miR-211-5p	(59)
Ivosidenib	It blocks Bruton's tyrosine kinase, and caused delaying progression of the cancer.	miR-183	(52)
	Inhibiting BRAF and cause apoptosis		

## Conclusion

Among the studied miRNAs, miR-99a and miR-181a play an essential role in apoptosis, proliferation, and oncogenesis via AKT, MAPK, RAS, and mTOR signaling pathways; while miR-223 and miR-125-a have function in apoptosis and oncogenesis via Wnt/B-catenin, PTEN/PI3K, STAT5/AKT/ERK/Src signaling pathways. miR100 is also common between apoptosis and oncogenesis, and act via IGF1 and mTOR signaling pathways. Paying attention to their dual role in causing apoptosis and proliferation and as an oncogenic factor, they could be used to design specific treatment methods, diagnostic panels, and screening programs in the high-risk patients.

## Journalism Ethics considerations

Ethical issues (Including plagiarism, informed consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc.) have been completely observed by the authors.

## Acknowledgements

The authors appreciate and thank the efforts of the Center for the Development of Clinical Researches of the Educational and Therapeutic Research Complex of Hazrat Rasool Akram.

## Conflict of interest

The authors declare that they have no conflict of interest.

## Data availability

This is a review study, and it is not an original. Data availability is corresponding author responsibility.

## Consent for publication

Not applicable.

## Funding

None

## References

1. Juliusson G, Hough R (2016). Leukemia. *Prog Tumor Res*,43:87-100.
2. Noroozi M, Ghazizadeh F, Fani S (2021). Blood component therapy, demographic and outcome feature of pediatric acute lymphoblastic leukemia. *J Prev Epidemiol*,6(2):e37-e.
3. Leukemia AM. Cancer Stat Facts. SEER Available online: [https://www.mybreastcancersupport.org/donate/?gclid=EAIAIQobChMIwZCMvKXYggMVitZ3Ch08ZAKMEAAAYASAAEgIQYfD\\_BwE](https://www.mybreastcancersupport.org/donate/?gclid=EAIAIQobChMIwZCMvKXYggMVitZ3Ch08ZAKMEAAAYASAAEgIQYfD_BwE) (accessed on 25 May 2020).
4. Meyers CA, Albitar M, Estey E (2005). Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. *Cancer*,104(4):788-93.
5. Wadai G (2022). Evaluation of Serum Interleukin-15 in Acute Lymphoid and Myeloid Leukemia Patients. *Arb Razq Inst*,77(5):1895-9.
6. Voso MT, Ottone T, Lavorgna S, et al (2019). MRD in AML: the role of new techniques. *Front Oncol*, 9:655.
7. Ghazizadeh F, Noroozi M, Shadara P, et al (2020). New therapy for chemotherapy-induced hepatic failure in leukemia; a randomized double-blind clinical trial study. *Immunopathol Persa*,7(2):e16-e.
8. Delgado J, Nadeu F, Colomer D, et al (2020). Chronic lymphocytic leukemia: From molecular pathogenesis to novel therapeutic strategies. *Haematologica*,105(9):2205-2217.
9. Cheung E, Perissinotti AJ, Bixby DL, et al (2019). The leukemia strikes back: a review of pathogenesis and treatment of secondary AML. *Ann Hematol*,98:541-59.



10. Hasanpour Dehkordi A, Keikhaei B, Bahadoram M, et al (2020). Keep the corners; impact of chemotherapy on renal function. *J Nephropathol*,9(1):e02.
11. Kotrová M, Koopmann J, Trautmann H, et al (2022). Prognostic value of low-level MRD in adult acute lymphoblastic leukemia detected by low-and high-throughput methods. *Blood Adv*,6(10):3006-10.
12. Della Starza I, Nunes V, Lovisa F, et al (2021). Droplet digital PCR improves ig-/tr-based mrd risk definition in childhood b-cell precursor acute lymphoblastic leukemia. *Hemasphere*, 5(3):e543.
13. Panuzzo C, Jovanovski A, Ali MS, et al (2022). Revealing the mysteries of acute myeloid leukemia: from quantitative PCR through next-generation sequencing and systemic metabolomic profiling. *J Clin Med*,11(3):483.
14. Rzepiel A, Kutzegi N, Egyed B, et al (2019). Circulating microRNAs as Potential Minimal Residual Disease Biomarkers in Pediatric Acute Lymphoblastic Leukemia. *J Transl Med*, 17(1):372.
15. Mahmoudian-Sani M-R, Mehri-Ghahfarrokhi A, Shojaeian A, et al (2018). The role of microRNAs in human cancers. *Immunopathol Persa*, 4(1):e05.
16. Satsar ES, Ghahremanfard F, Farahani MM, et al (2019). Bi-lineage acute leukemia; a case with B-lymphoblasts and myeloid blasts. *J Prev Epidemiol*, 4(2):e14-e.
17. El-Khazragy N, Noshi MA, Abdel-Malak C, et al (2019). miRNA-155 and miRNA-181a as prognostic biomarkers for pediatric acute lymphoblastic leukemia. *J Cell Biochem*, 120(4):6315-21.
18. Stepicheva NA, Song JL (2016). Function and regulation of microRNA-31 in development and disease. *Mol Reprod Dev*, 83(8):654-74.
19. Shete MV, Deshmukh RS, Kulkarni T, et al (2020). Myofibroblasts as important diagnostic and prognostic indicators of oral squamous cell carcinoma: An immunohistochemical study in normal oral mucosa, epithelial dysplasia, and oral squamous cell carcinoma. *J Carcinog*, 19:1.
20. Sanjaya A (2022). microRNA-379 as a Candidate Biomarker for Early Diagnosis of Childhood Active and Latent Tuberculosis.
21. Shahad FAA-Z, Mohammed AA, Jasim GA (2022). YKL-40 as a novel diagnostic biomarker in Toxoplasmosis. *J Popul Ther Clin Pharmacol*, 29(2):e61-e70.
22. Farsaeivahid N, Grenier C, Nazarian S, et al (2022). A Rapid Label-Free Disposable Electrochemical Salivary Point-of-Care Sensor for SARS-CoV-2 Detection and Quantification. *Sensors (Basel)*, 23(1):433.
23. Zhao H, Wang D, Du W, et al (2010). MicroRNA and leukemia: tiny molecule, great function. *Crit Rev Oncol Hematol*, 74(3):149-55.
24. Lalfamkima F, Georgeno G, Rao NK, et al (2021). Clinical diagnostic criteria versus advanced imaging in prediction of cervical lymph node metastasis in oral squamous cell carcinomas: A magnetic resonance imaging based study. *J Carcinog*, 20:3.
25. Erkeland SJ, Stavast CJ, Schilperoord-Vermeulen J, et al (2022). The miR-200c/141-ZEB2-TGF $\beta$  axis is aberrant in human T-cell prolymphocytic leukemia. *Haematologica*, 107(1):143-153.
26. Garousi M, Tabar SM, Mirzai H, et al (2022). A global systematic review and meta-analysis on correlation between biofilm producers and non-biofilm producers with antibiotic resistance in Uropathogenic Escherichia coli. *Microb Pathog*, 164:105412.
27. Saleem Abd Alkreem Alsaqi S (2022). Immunohistochemical and Electron Microscopy Evolution in the Diagnosis of Lung Cancer in Iraq. *Arab Razzi Inst*, 77(1):95-100.
28. Rao S, Anthony ML, Chowdhury N, et al (2021). Molecular characterization of lung carcinomas: A study on diagnostic, predictive, and prognostic markers using immunohistochemical analysis at a Tertiary Care Center in Uttarakhand, India. *J Carcinog*, 20:17.
29. Palacios F, Prieto D, Abreu C, et al (2015). Dissecting chronic lymphocytic leukemia microenvironment signals in patients with unmutated disease: microRNA-22 regulates phosphatase and tensin homolog/AKT/FOXO1 pathway in proliferative leukemic cells. *Leuk Lymphoma*, 56(5):1560-5.
30. Zhou J-d, Li X-x, Zhang T-j, et al (2019). MicroRNA-335/ID4 dysregulation predicts

- clinical outcome and facilitates leukemogenesis by activating PI3K/Akt signaling pathway in acute myeloid leukemia. *Aging (Albany NY)*, 11(10):3376-3391.
31. Heyn H, Engelmann M, Schreek S, et al (2011). MicroRNA miR-335 is crucial for the BRCA1 regulatory cascade in breast cancer development. *Int J Cancer*, 129(12):2797-806.
  32. Zhang M, Xiong F, Zhang S, et al (2022). Crucial roles of miR-625 in human cancer. *Front Med (Lausanne)*, 9:845094.
  33. Thessing A, Ayres R, Jones J, et al (2022). Oxa-Michael/Ugi-Smiles cascade reaction with  $\alpha$ ,  $\beta$ -unsaturated aldehydes. *Results in Chemistry*, 4:100416.
  34. Aliabedi B, Mousavi SH, Ebrahimi M, et al (2022). Hsa-miR-625 Upregulation Promotes Apoptosis in Acute Myeloid Leukemia Cell Line by Targeting Integrin-linked Kinase Pathway. *Asian Pac J Cancer Prev*, 23(4):1159-67.
  35. Li X, Luo X, Han B, et al (2013). MicroRNA-100/99a, deregulated in acute lymphoblastic leukaemia, suppress proliferation and promote apoptosis by regulating the FKBP51 and IGF1R/mTOR signalling pathways. *Br J Cancer*, 109(8):2189-98.
  36. Al-Dulaimi TH, Bunyan IA, Banimuslem TA (2022). Genomic Analysis study of Virulence Potential  $\hat{\pm}$ -hemolysin from Uropathogenic E. coli. *J Complement Med Res*, 13(4):164.
  37. Li Y, Gao L, Luo X, et al (2013). Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t (8; 21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway. *Blood*, 121(3):499-509.
  38. Al-Harbi S, Aljurf M, Mohty M, et al (2020). An update on the molecular pathogenesis and potential therapeutic targeting of AML with t (8; 21)(q22; q22. 1); RUNX1-RUNX1T1. *Blood Adv*, 4(1):229-38.
  39. Zahir ST, Hesami M, Gharaeikhezri A, et al (2021). The Evaluation of the recurrence and survival in patients with papillary thyroid cancer: A retrospective Study. *P J M H S*, 15(3):1074-7.
  40. Marquez ME, Sembo S, Payque E, et al (2022). TGF- $\beta$ /SMAD Pathway is modulated by miR-26b-5p: another piece in the puzzle of chronic lymphocytic leukemia progression. *Cancers (Basel)*, 14(7):1676.
  41. Rastegarpouyani H, Mohebbi SR, Hosseini SM, et al (2018). Detection of Parvovirus 4 in Iranian patients with HBV, HCV, HIV mono-infection, HIV and HCV co-infection. *Gastroenterol Hepatol Bed Bench*, 11(2): 138-44.
  42. Saberian P, Hesami M, Tavakoli N, et al (2022). At-risk COVID-19 Patients; Knowledge and Attitude of Those in Need of Transfer to Hospital and Consequences in Non-transferred Patients. *Health Scope*, 11(1): e119063.
  43. Tahermanesh K, Hanjani S, Saadat Mostafavi SR, et al (2022). Hourglass cesarean scar: A neglected external niche in association with the internal niche. *Int J Gynaecol Obstet*, 157(2):478-480.
  44. Elias MH, Syed Mohamad SF, Abdul Hamid N (2022). A Systematic Review of Candidate miRNAs, Its Targeted Genes and Pathways in Chronic Myeloid Leukemia-An Integrated Bioinformatical Analysis. *Front Oncol*, 12:848199.
  45. Ufkin ML, Peterson S, Yang X, et al (2014). miR-125a regulates cell cycle, proliferation, and apoptosis by targeting the ErbB pathway in acute myeloid leukemia. *Leuk Res*, 38(3):402-10.
  46. Zhang R, Tang P, Wang F, et al (2019). Tumor suppressor miR-139-5p targets Tspan3 and regulates the progression of acute myeloid leukemia through the PI3K/Akt pathway. *J Cell Biochem*, 120(3):4423-4432.
  47. Lv M, Zhang X, Jia H, et al (2012). An oncogenic role of miR-142-3p in human T-cell acute lymphoblastic leukemia (T-ALL) by targeting glucocorticoid receptor- $\alpha$  and cAMP/PKA pathways. *Leukemia*, 26(4):769-77.
  48. Yuan T, Yang Y, Chen J, et al (2017). Regulation of PI3K signaling in T-cell acute lymphoblastic leukemia: a novel PTEN/Ikaros/miR-26b mechanism reveals a critical targetable role for PIK3CD. *Leukemia*, 31(11):2355-64.
  49. Behboodi R, Saadati Partan A, Meidaninikjeh S, et al (2023). Clostridium Bacteria: The Team of Microscopic Oncologists. *IJBC*, 15(4):178-202.
  50. Liu N-w, Huang X, Liu S, et al (2019). EXT1, regulated by MiR-665, promotes cell apoptosis via ERK1/2 signaling pathway in

- acute lymphoblastic leukemia. *Med Sci Monit*, 25:6491.
51. Nie D, Ma P, Chen Y, et al (2021). MiR-204 suppresses the progression of acute myeloid leukemia through HGF/c-Met pathway. *Hematology*,26(1):931-9.
  52. Kadhem Mallakh M, Mohammed Mahmood M, Hasan Mohammed Ali S (2022). Immunomolecular Investigation of Human Papillomavirus Genotypes (16, 18) and P63 Expression in Patients with Malignant and Non-malignant Colorectal Tumors. *Arab Razzi Inst*,77(1):383-90.
  53. Faridnejad H (2022). The impact of physicochemical modification on iron oxide nanoparticle relaxation enhancement in biomedical imaging in the anticancer sector. *Scholars Research Journal*,10(2):26-33.
  54. Su R, Dong L, Zou D, et al (2016). microRNA-23a,-27a and-24 synergistically regulate JAK1/Stat3 cascade and serve as novel therapeutic targets in human acute erythroid leukemia. *Oncogene*, 35(46):6001-14.
  55. Huang X, Schwind S, Santhanam R, et al (2016). Targeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemia. *Oncotarget*,7(37):59273-59286.
  56. Wang LQ, Wong KY, Rosèn A, et al (2015). Epigenetic silencing of tumor suppressor miR-3151 contributes to Chinese chronic lymphocytic leukemia by constitutive activation of MADD/ERK and PIK3R2/AKT signaling pathways. *Oncotarget*,6(42):44422-36.
  57. Ghiasi F, Hosseinzadeh Z, Nemati F, et al (2021). The Effect of Cognitive-Behavioral Therapy (CBT) on Anxiety Reduction in Critical Care Unit (CCU) Patients During Hospitalization. *Journal of Intellectual Disability-Diagnosis and Treatment*,9(3):304-10.
  58. Ma J, Wu D, Yi J, et al (2019). MiR-378 promoted cell proliferation and inhibited apoptosis by enhanced stem cell properties in chronic myeloid leukemia K562 cells. *Biomed Pharmacother*, 112:108623.
  59. Wang Z, Ma B, Ji X, et al (2015). MicroRNA-378-5p suppresses cell proliferation and induces apoptosis in colorectal cancer cells by targeting BRAF. *Cancer Cell Int*, 15:40.
  60. Afaghi S, Esmaeili Tarki F, Sadat Rahimi F, et al (2021). Prevalence and Clinical Outcomes of Vitamin D Deficiency in COVID-19 Hospitalized Patients: A Retrospective Single-Center Analysis. *Toboku J Exp Med*, 255(2):127-134.
  61. Gu Y, Si J, Xiao X, et al (2017). miR-92a inhibits proliferation and induces apoptosis by regulating methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) expression in acute myeloid leukemia. *Oncol Res*, 25(7):1069-1079.
  62. Alwaeely FA, Alsaadi MAK, Madlum KN (2021). Immunomodulatory Effect of Propolis on IFN- $\gamma$ , IL-17A and IL-23 Production in Human Peripheral Blood Mononuclear Cells Treated with *Pseudomonas aeruginosa* Ag. *jchr*;11(Special Issue: Bioactive Compounds: Their Role in the Prevention and Treatment of Diseases),143-51.
  63. Nie Z-Y, Liu X-J, Zhan Y, et al (2019). miR-140-5p induces cell apoptosis and decreases Warburg effect in chronic myeloid leukemia by targeting SIX1. *Biosci Rep*, 39(4):BSR20190150.
  64. Wang X, Feng Y, Zhang P, et al (2020). miR-582-5p serves as an antioncogenic biomarker in intermediate risk AML with normal cytogenetics and could inhibit proliferation and induce apoptosis of leukemia cells. *Cell Biol Int*, 44(10):2021-2030.
  65. Hu Y, Ma X, Wu Z, et al (2020). MicroRNA-34a-mediated death of acute myeloid leukemia stem cells through apoptosis induction and exosome shedding inhibition via histone deacetylase 2 targeting. *IUBMB Life*,72(7):1481-90.
  66. Sun Y, Wang H, Luo C (2020). MiR-100 regulates cell viability and apoptosis by targeting ATM in pediatric acute myeloid leukemia. *Biochem Biophys Res Commun*, 522(4):855-861.
  67. Liu H, Ni Z, Shi L, et al (2019). MiR-486-5p inhibits the proliferation of leukemia cells and induces apoptosis through targeting FOXO1. *Mol Cell Probes*, 44:37-43.
  68. Fei J, Li Y, Zhu X, et al (2012). miR-181a post-transcriptionally downregulates oncogenic RalA and contributes to growth inhibition and apoptosis in chronic myelogenous leukemia (CML). *PLoS One*, 7(3):e32834.
  69. Chen X, Yang S, Zeng J, et al (2019). miR-1271-5p inhibits cell proliferation and

- induces apoptosis in acute myeloid leukemia by targeting ZIC2. *Mol Med Rep*, 19(1):508-514.
70. Jiang T, Chen J, Huang X, et al (2018). miR-451a induced apoptosis of Philadelphia chromosome-positive acute lymphoblastic leukemia cells by targeting IL-6R. *Neoplasma*,65(6):907-14.
  71. Tian C, You MJ, Yu Y, et al (2016). MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1. *Tumour Biol*, 37(6):7461-71.
  72. Li G, Song Y, Li G, et al (2018). Downregulation of microRNA-21 expression inhibits proliferation, and induces G1 arrest and apoptosis via the PIEN/AKT pathway in SKM-1 cells. *Mol Med Rep*,18(3):2771-9.
  73. Garzon R, Heaphy CE, Havelange V, et al (2009). MicroRNA 29b functions in acute myeloid leukemia. *Blood*,114(26):5331-41.
  74. Wang Y, Tang P, Chen Y, et al (2017). Overexpression of microRNA-125b inhibits human acute myeloid leukemia cells invasion, proliferation and promotes cells apoptosis by targeting NF- $\kappa$ B signaling pathway. *Biochem Biophys Res Commun*,488(1):60-66.
  75. Ding Q, Wang Q, Ren Y, et al (2018). MicroRNA-126 attenuates cell apoptosis by targeting TRAF7 in acute myeloid leukemia cells. *Biochem Cell Biol*,96(6):840-6.
  76. Xu H, Wen Q (2018). Downregulation of miR-135a predicts poor prognosis in acute myeloid leukemia and regulates leukemia progression via modulating HOXA10 expression. *Mol Med Rep*,18(1):1134-40.
  77. Hartmann J-U, Bräuer-Hartmann D, Kardosova M, et al (2018). MicroRNA-143 targets ERK5 in granulopoiesis and predicts outcome of patients with acute myeloid leukemia. *Cell Death Dis*, 9(8):814.
  78. Fang ZH, Wang SL, Zhao JT, et al (2016). miR-150 exerts antileukemia activity in vitro and in vivo through regulating genes in multiple pathways. *Cell Death Dis*, 7(9):e2371.
  79. Yan Z-X, Zheng Z, Xue W, et al (2015). MicroRNA181a is overexpressed in T-cell leukemia/lymphoma and related to chemoresistance. *Biomed Res Int*, 2015:197241.
  80. Shen L, Du X, Ma H, et al (2017). miR-1193 suppresses the proliferation and invasion of human T-cell leukemia cells through directly targeting the transmembrane 9 superfamily 3 (TM9SF3). *Oncol Res*,25(9):1643-51.
  81. Choi J, Kim Y-K, Park K, et al (2016). MicroRNA-139-5p regulates proliferation of hematopoietic progenitors and is repressed during BCR-ABL-mediated leukemogenesis. *Blood*, 128(17):2117-29.
  82. Bao J, Li X, Li Y, et al (2020). MicroRNA-141-5p acts as a tumor suppressor via targeting RAB32 in chronic myeloid leukemia. *Front Pharmacol*, 10:1545.
  83. Tavolaro S, Colombo T, Chiaretti S, et al (2015). Increased chronic lymphocytic leukemia proliferation upon IgM stimulation is sustained by the upregulation of miR-132 and miR-212. *Genes Chromosomes Cancer*,54(4):222-34.
  84. Hornick NI, Huan J, Doron B, et al (2015). Serum exosome microRNA as a minimally-invasive early biomarker of AML. *Sci Rep*, 5:11295.
  85. Fasihi-Ramandi M, Moridnia A, Najafi A, et al (2017). Inducing cell proliferative prevention in human acute promyelocytic leukemia by miR-182 inhibition through modulation of CASP9 expression. *Biomed Pharmacother*, 89:1152-1158.
  86. Braga TV, Evangelista FCG, Gomes LC, et al (2017). Evaluation of MiR-15a and MiR-16-1 as prognostic biomarkers in chronic lymphocytic leukemia. *Biomed Pharmacother*,92:864-9.
  87. Liang Y-N, Tang Y-L, Ke Z-Y, et al (2017). MiR-124 contributes to glucocorticoid resistance in acute lymphoblastic leukemia by promoting proliferation, inhibiting apoptosis and targeting the glucocorticoid receptor. *J Steroid Biochem Mol Biol*, 172:62-8.
  88. Jia CY, Li HH, Zhu XC, et al (2011). MiR-223 suppresses cell proliferation by targeting IGF-1R. *PLoS One*, 6(11):e27008.
  89. Rahmani F, Safavi P, Fathollahpour A, et al (2022). The interplay between non-coding RNAs and Wnt/ $\beta$ -catenin signaling pathway in urinary tract cancers: from tumorigenesis to metastasis. *EXCLI J*, 21:1273-1284.
  90. Sha C, Jia G, Jingjing Z, et al (2021). miR-486 is involved in the pathogenesis of acute myeloid leukemia by regulating JAK-STAT signaling.



- Naumyn Schmiedebergs Arch Pharmacol*, 394:177-87.
91. Emmrich S, Katsman-Kuipers J, Henke K, et al (2014). miR-9 is a tumor suppressor in pediatric AML with t (8; 21). *Leukemia*,28(5):1022-32.
  92. Ahadi HR, Sadrabadi AE, Jalili A, et al (2022). Association of Interleukin 10 (IL-10) Gene Polymorphism (819T > C) with Susceptibility to Acute Myeloid Leukemia: A Meta-Analysis. *Iran J Public Health*, 51(1):19-26.
  93. Zhou L, Fu L, Lv N, et al (2017). A minicircuitry comprised of microRNA-9 and SIRT1 contributes to leukemogenesis in t (8; 21) acute myeloid leukemia. *Eur Rev Med Pharmacol Sci*, 21(4):786-94.
  94. Senyuk V, Zhang Y, Liu Y, et al (2013). Critical role of miR-9 in myelopoiesis and EVI1-induced leukemogenesis. *Proc Natl Acad Sci U S A*, 110(14):5594-9.
  95. Liu S, Wu L-C, Pang J, et al (2010). Sp1/NF $\kappa$ B/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. *Cancer Cell*, 17(4):333-47.
  96. Pulikkan JA, Peramangalam PS, Dengler V, et al (2010). C/EBP $\alpha$  regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations. *Blood*, 116(25):5638-49.
  97. Sharma S, Rai KR (2019). Chronic lymphocytic leukemia (CLL) treatment: So many choices, such great options. *Cancer*, 125(9):1432-40.
  98. Thol F, Ganser A (2020). Treatment of relapsed acute myeloid leukemia. *Curr Treat Options Oncol*, 21(8):66.
  99. Pekarsky Y, Balatti V, Croce CM (2018). BCL2 and miR-15/16: from gene discovery to treatment. *Cell Death Differ*, 25(1):21-26.
  100. Zaaan MA, Abdelhamid AM (2022). Dasatinib ameliorates thioacetamide-induced liver fibrosis: modulation of miR-378 and miR-17 and their linked Wnt/ $\beta$ -catenin and TGF- $\beta$ /smads pathways. *J Enzyme Inhib Med Chem*, 37(1):118-24.